Palmidrol
Small molecule targets PPARA via activation
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07330765 | Jan 2026 → Oct 2027 expected | — | Abdelrahman Gaber Sayed Elkhateeb | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05766969 | Jun → Dec 2023 | diabetic polyneuropathy | Pure Green Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05126888 | Jun 2026 → Oct 2027 expected | Tourette syndrome | Neurothera Labs Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06273462 | Aug 2024 → Aug 2025 overdue | chronic pain syndrome | Navy Medical Center San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT06229977 | May 2023 → Jul 2025 | bipolar depression | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT05652907 | Jan → May 2023 | idiopathic mast cell activation syndrome | Quantum Biopharma | Terminated | No outcome recorded |
| Phase 2 | NCT06063369 | Dec 2022 → Dec 2023 | bipolar depression, major depressive disorder | The Israeli Medical Center for Alzheimer's | Unknown | No outcome recorded |
| Phase 2 | NCT05246670 | May 2022 → Feb 2024 overdue | cancer, chemotherapy-induced neuropathy, hematopoietic and lymphoid cell neoplasm | Academic and Community Cancer Research United | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04619706 | Dec 2020 → Aug 2021 | COVID-19 | Quantum Biopharma | Terminated | No outcome recorded |
| Phase 2 | NCT04091789 | Sep 2019 → Mar 2020 | dysmenorrhea, migraine disorder, mood disorder | Pure Green | Unknown | No outcome recorded |
| Phase 2 | NCT03066193 | Feb 2017 → Jun 2018 | Tourette syndrome | Yale University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05003453 | Nov 2021 → Jun 2022 | atopic eczema | RDC Clinical Pty Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05046522 | Sep 2021 → Mar 2023 | migraine disorder | RDC Clinical Pty Ltd | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07013890 | Nov 2022 → Aug 2023 | chronic prostatitis | Clinica Urologica Molinette - Città della Saliute e della Scienza | Completed | No outcome recorded |
| Phase 4 | NCT04853836 | Nov 2020 → Oct 2021 | COVID-19, anosmia | University Of Perugia | Completed | No outcome recorded |
| Phase 4 | NCT04488926 | Jul 2020 → May 2022 | fibromyalgia | Epitech Group SpA | Completed | No outcome recorded |
| Phase 4 | NCT02699281 | Oct 2015 → Jul 2016 | chronic pain syndrome | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07305519 | Apr 2026 → Apr 2027 expected | — | University of Roma La Sapienza | Recruiting | No outcome recorded |
| — | NCT07316660 | Jan → Jun 2026 overdue | — | Benha University | Not yet recruiting | No outcome recorded |
| — | NCT05182697 | Feb 2024 → May 2026 overdue | autism spectrum disorder | Neurothera Labs Inc. | Recruiting | No outcome recorded |
| — | NCT05877170 | Feb 2020 → Aug 2023 | — | University of Catania | Unknown | No outcome recorded |
| — | NCT02645461 | Jan 2014 → Jun 2015 | amyotrophic lateral sclerosis | University of Roma La Sapienza | Completed | No outcome recorded |
| — | NCT02372903 | Oct 2013 → Aug 2015 | chronic pain syndrome, endometriosis | University of Cagliari | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05480072 Comparator | Nov 2022 → Jan 2025 | substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05317676 Comparator | May 2023 → Dec 2024 | — | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05810116 Comparator | May → Dec 2023 | dysmenorrhea | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Palmidrol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05246670 ↗ |
| Known as | AM 3112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | CannAmide | “Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily” NCT05182697 ↗ |
| Known as | FSD201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05652907 ↗ |
| Known as | Impulsin | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Levagen + | “Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21” NCT05480072 ↗1“Palmitoylethanolamide sold as Levagen +” NCT05046522 ↗ |
| Known as | Loramine p 256 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | mPEA | “micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules” NCT04488926 ↗ |
| Known as | N(2-hydroxyethyl) palmitide | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | NSC-23320 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Palmdrol prodes | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Palmidrol component of sci-110 palmitoylethanolamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Palmitamide mea | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Palmitic acid monoethanolamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | Palmitic monoethanolamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | palmitoylethanolamide | “Palmitoylethanolamide (PEA) is a bioactive lipid mediator similar to endocannabinoids (eCBs) that has been observed to have anti-inflammatory, analgesic, anticonvulsant,...” NCT05877170 ↗22“A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg.” NCT05126888 ↗ “The studies evaluated the following interventions: systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant and palmitoylethanolamide plus luteolin.” PMID 36062970 ↗ Sep 2022 “A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet” NCT05766969 ↗ “Effect of Palmitoylethanolamide (PEA) Compared to a Placebo on Acute Menstrual Pain in an Adult Population - a Double-blind, Crossover, Randomised Controlled Trial.” NCT05810116 ↗ “Palmitoylethanolamide (PEA), an endogenous bioactive lipid, exerts anti-inflammatory and mast-cell-stabilizing properties” NCT07305519 ↗ “Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes” NCT04488926 ↗ “One of the most widely studied NAEs is the analgesic endocannabinoid compound, palmitoylethanolamide (PEA).” NCT07330765 ↗ “Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily” NCT05182697 ↗ |
| Known as | PEA | “Palmitoylethanolamide (PEA) is a bioactive lipid mediator similar to endocannabinoids (eCBs) that has been observed to have anti-inflammatory, analgesic, anticonvulsant,...” NCT05877170 ↗10“A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg.” NCT05126888 ↗ “Palmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies.” NCT07316660 ↗ “Effect of Palmitoylethanolamide (PEA) Compared to a Placebo on Acute Menstrual Pain in an Adult Population - a Double-blind, Crossover, Randomised Controlled Trial.” NCT05810116 ↗ “Palmitoylethanolamide (PEA) is an endogenous widely distributed N-acylethanolamina involved in neuroinflammation and pain-generating processes.” NCT02699281 ↗ “Palmitoylethanolamide (PEA), an endogenous bioactive lipid, exerts anti-inflammatory and mast-cell-stabilizing properties” NCT07305519 ↗ “One of the most widely studied NAEs is the analgesic endocannabinoid compound, palmitoylethanolamide (PEA).” NCT07330765 ↗ “Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily” NCT05182697 ↗ “Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin” NCT02372903 ↗ “Palmitoylethanolamide (PEA)” NCT06229977 ↗ |
| Known as | Pea (chemical) | ChEMBL registry synonym — accepted as the source's own label CHEMBL417675 ↗ |
| Known as | umPEA | “micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules” NCT04488926 ↗ |
| Action | Activate | “PEA has potent immunoregulatory and anti-inflammatory effects by directly activating PPAR-α” NCT06063369 ↗ |
| Modality | Small molecule | “Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide” NCT06273462 ↗ |
| Route | Other | “Palmitoylethanolamide 600 mg twice daily for 10 days sublingually” NCT02372903 ↗ |
| Target | PPARA | “interacting with peroxisome proliferator-activated receptor alpha (PPAR-α)” NCT06273462 ↗ |